International Journal of Cancer Care and Delivery’s Post

Pan-cancer biomarkers and therapies are an exciting development in the field of cancer treatment, as they offer new hope for patients who may not have precision therapies developed for their specific disease. The growth of our INFORM clinical-genomics database is also exciting, as it provides the evidence to refine ever more targeted therapies. Let's continue to push the boundaries of cancer research and treatment! #cancerresearch #precisionmedicine #clinicalgenomics

Guardant360 #liquidbiopsy is well-validated to detect microsatellite instability high tumors and those same patients treated with FDA approved immunotherapy have better outcomes. This is a great set of #pancancer #multicancer cohort data and goes far in showing that guidelines and coverage policies can include #comprehensivegenomicprofiling in a specimen and tumor agnostic manner. Great work on this paper!!!

RINGSIDE phase 2 data in desmoid tumors show that AL102 1.2 mg once daily achieved ORR of 83% and reduction in tumor volume and in T2W signal intensity in 88% and 85% of the evaluable population, respectively. The Ayala team is very grateful to the patients, their families and the investigators participating in the study. #desmoid #GSI #AL102 #RINGSIDE

The findings in the peer-reviewed research published by JAMA Oncology signify a major advancement in the ability to make highly accurate, comprehensive and personalized predictions about the risk of clinically significant #prostatecancer. As Lynx Dx Chief Medical and Commercial Officer, Spencer Heaton, notes: “The research findings demonstrate the potential of MPS2 to facilitate more informed decision-making about a patient’s best course of treatment by shedding new light on a serious condition that is notoriously difficult to diagnose.” Read the full announcement: https://lnkd.in/gwKU_Tun #ProstateCancer #Innovation #CancerResearch

Ongoing efforts to expand the armamentarium of cell surface targets (DLL3 in this case, for high grade neuroendocrine neoplams) which can be imaged by radionuclide-based tracers. These types of tracers may expand and refine the choice of candidate patients eligible for targeted therapies (e.g., ADCs, radioligand therapy) while moving beyond our reliance on tissue IHC which can be limited by sample availability and heterogeneity

We've been diving into some trends in current clinical trials for antibody-drug conjugates (ADCs), focusing particularly on the types of antibodies used and their target antigens. A review article by Edidiong U. et al. from the University of Illinois Chicago discusses over 500 active clinical trials investigating newer ADCs and addresses the challenges associated with their clinical translation. Here are some key points we found interesting: ➡️ Of all active clinical trials, only 36% focus on new ADCs. Interestingly, 90% of these new ADC trials target solid tumor applications, marking a significant shift from already approved ADCs. ➡️ 80% of trials target established antigens for hematological and solid tumors, including HER2 (32%), CD30 (14%), and TROP2 (9%). However, there is a growing interest in targeting novel antigens, which accounts for 20% of clinical trials. This push for novel antigens is likely driven by the expanding application of ADCs to solid tumors. Check out the article here: https://lnkd.in/gWEB9eZG #ADCs #AntibodyDrugConjugates #AntibodyTherapeutics #DrugDiscovery #AntibodyDiscovery

One of our resident TIL experts, Chantale Bernatchez, shares her insights about the future of TIL therapy. She addresses the challenges of manufacturing this complex therapy while explaining the inherent properties of TILs that give them an advantage over other therapies: preselection by the body to recognize specific tumors and the ability to target multiple antigens. Learn more about the role CTMC is playing to bring TILs into the clinic for our partners. #biotech #celltherapy #tiltherapy #endcancer https://lnkd.in/g44Hu2bH

Dear friends at Seagen and Pfizer, could anyone help here?!! Please reach out to the study team responsible for the study & region. Jake’s tumour is unfortunately back to growth mode (fuck!!) and his wash out period is the 13th of April! The trials he is after are #ADC trials but the sites are not yet initiated!!! “I thought (incorrectly, it appears) that UCSD would host Seagen’s “A Study of SGN-PDL1V in Advanced Solid Tumors,” but there are two issues: one is that there are actually two different Seagen trials that I’m eligible for. The other is that there’ve been delays in opening a Seagen trial at UCSD. My tumors are growing too fast to wait around to see when it might open.” To my friends who connect patients with Clinical trials: Brandon Li, Massive Bio, Maya Zlatanova, could you assist Bess and Jake here? Please. Cc: b2venture, HEARTFELT_ , Lennart Boesch, Joerg Rheinboldt, Jan-Hendrik Buerk that’s why the speed of site selection and study startup matter 💙 https://lnkd.in/ewMepXAJ

“Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.” There are more than 150 active INDs associated with BRAF targeted and combination therapy across all indications. This is the second largest sub population solid tumor active efforts in precision medicine in R/R groups. Combinations are increasing along T & B cell combination targets.

Proud to have been able to contribute to this research. Another great article, assessing ADC and recombinant photo-activated therapeutic efficacy for light-accessible and light-inaccessible tumors. https://lnkd.in/dFwTibUM